Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002945 · ClinicalTrials.gov registry record · Phase 3
High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia
A Phase 3 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 3
- Development phase
- 61
- Enrollment target
NCT00002945 is a Phase 3 study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 61 participants.
The verdict
NCT00002945, a Phase 3 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 61 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Interleukin-2 may stimulate a person's white blood cells to kill leukemia cells. PURPOSE: Phase III trial to study the effectiveness of high-dose combination chemotherapy, peripheral stem cell transplantation, and interleukin-2 in treating patients who have acute myeloid leukemia.
Interventions
- DRUG cyclophosphamide
- DRUG etoposide
- BIOLOGICAL aldesleukin
- BIOLOGICAL filgrastim
- DRUG cytarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 1996-12 |
| Est. Completion | 2011-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002945
The ClinicalTrials.gov registry entry for NCT00002945 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00002945 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002945 about?
NCT00002945 is a clinical study titled "High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Interleukin-2 may stim...
What is the current status of trial NCT00002945?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 61 participants. The study started on 1996-12. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00002945?
The interventions under investigation include: cyclophosphamide (DRUG), etoposide (DRUG), aldesleukin (BIOLOGICAL), filgrastim (BIOLOGICAL), cytarabine (DRUG).
Who is sponsoring clinical trial NCT00002945?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.